Program Objective
The rate of new cases of type 2 diabetes has nearly doubled in the United States in the last decade.However, despite numerous therapeutic options,glycemic control has not substantially improved in recent years. A new understanding of specialized incretin—or gut—hormones is leading significant advances in the treatment and management of type 2 diabetes.

The availability of a new class of agents,GLP-1 agonists, is providing greater insights on how these agents can be used as part of success fultreatment approaches for patients with type 2 diabetes. Using a case-based approach, including questions/challenges that might be encountered from patients with prescriptions for GLP-1 agonists, this continuing pharmacy education program will provide pharmacists with practical information they can communicate to and educate patients about the features and benefits of newer treatment options for type 2 diabetes.

Click here for lesson